168 related articles for article (PubMed ID: 35338607)
1. Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing.
Zhou H; Wang X; Steer CJ; Song G; Niu J
Hepatol Commun; 2022 Jul; 6(7):1652-1663. PubMed ID: 35338607
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
[TBL] [Abstract][Full Text] [Related]
3. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
4. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
5. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
6. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
7. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
8. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
9. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
10. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.
Wang J; Xu ZW; Liu S; Zhang RY; Ding SL; Xie XM; Long L; Chen XM; Zhuang H; Lu FM
World J Gastroenterol; 2015 Aug; 21(32):9554-65. PubMed ID: 26327763
[TBL] [Abstract][Full Text] [Related]
11. High-Fidelity Cytosine Base Editing in a GC-Rich Corynebacterium glutamicum with Reduced DNA Off-Target Editing Effects.
Heo YB; Hwang GH; Kang SW; Bae S; Woo HM
Microbiol Spectr; 2022 Dec; 10(6):e0376022. PubMed ID: 36374037
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-CBEI: a Designing and Analyzing Tool Kit for Cytosine Base Editor-Mediated Gene Inactivation.
Yu H; Wu Z; Chen X; Ji Q; Tao S
mSystems; 2020 Sep; 5(5):. PubMed ID: 32963098
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons.
Billon P; Bryant EE; Joseph SA; Nambiar TS; Hayward SB; Rothstein R; Ciccia A
Mol Cell; 2017 Sep; 67(6):1068-1079.e4. PubMed ID: 28890334
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
Liu X; Hao R; Chen S; Guo D; Chen Y
J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
[TBL] [Abstract][Full Text] [Related]
16. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression
Smekalova EM; Martinez MG; Combe E; Kumar A; Dejene S; Leboeuf D; Chen CY; Dorkin JR; Shuang LS; Kieft S; Young L; Barrera LA; Packer MS; Ciaramella G; Testoni B; Gregoire F; Zoulim F
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102112. PubMed ID: 38292874
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.
Kato Y; Tabata H; Sato K; Nakamura M; Saito I; Nakanishi T
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638909
[TBL] [Abstract][Full Text] [Related]
18. Design of a generic CRISPR-Cas9 approach using the same sgRNA to perform gene editing at distinct loci.
Najah S; Saulnier C; Pernodet JL; Bury-Moné S
BMC Biotechnol; 2019 Mar; 19(1):18. PubMed ID: 30894153
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of single guide RNA transcription for efficient CRISPR/Cas-based genomic engineering.
Ui-Tei K; Maruyama S; Nakano Y
Genome; 2017 Jun; 60(6):537-545. PubMed ID: 28177825
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus.
Zhen S; Hua L; Liu YH; Gao LC; Fu J; Wan DY; Dong LH; Song HF; Gao X
Gene Ther; 2015 May; 22(5):404-12. PubMed ID: 25652100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
